Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1976
Insight Enterprises
NSIT
$4.53B
| $4.13M | ﹤0.01% |
58,773
-65,698
| -53% | -$4.14M |
|
|
MRSN
1977
DELISTED
Mersana Therapeutics
MRSN
| $4.12M | ﹤0.01% |
28,791
-1,878
| -6% | -$137K |
|
1978
The Greenbrier Companies
GBX
$1.41B
| $4.12M | ﹤0.01% |
+127,100
| New | +$3.81M |
|
|
MASI
1979
DELISTED
Masimo
MASI
| $4.11M | ﹤0.01% |
26,021
-78,679
| -75% | -$11.8M |
|
1980
Aviat Networks
AVNW
$287M
| $4.09M | ﹤0.01% |
582,170
-400
| -0.1% | -$2.81K |
|
1981
Cactus
WHD
$5.88B
| $4.07M | ﹤0.01% |
118,500
-178,900
| -60% | -$5.43M |
|
1982
Airgain
AIRG
$72.2M
| $4.06M | ﹤0.01% |
379,410
+63,100
| +20% | +$663K |
|
1983
LCNB Corp
LCNB
$283M
| $4.05M | ﹤0.01% |
209,616
+2,200
| +1% | +$40.2K |
|
|
FLY
1984
DELISTED
Fly Leasing Limited
FLY
| $4.04M | ﹤0.01% |
206,118
-77,607
| -27% | -$1.55M |
|
1985
Genie Energy
GNE
$383M
| $4.04M | ﹤0.01% |
522,097
+700
| +0.1% | +$5.49K |
|
1986
argenx
ARGX
$53.3B
| $4.03M | ﹤0.01% |
25,091
-409
| -2% | -$55.3K |
|
|
IVAC
1987
DELISTED
Intevac Inc
IVAC
| $4.02M | ﹤0.01% |
569,645
+20,236
| +4% | +$118K |
|
1988
Zumiez
ZUMZ
$314M
| $4.01M | ﹤0.01% |
116,200
+80,300
| +224% | +$2.54M |
|
1989
ORIX
IX
$43.6B
| $4.01M | ﹤0.01% |
240,500
+47,500
| +25% | +$762K |
|
|
VCRA
1990
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $4.01M | ﹤0.01% |
193,087
+40,987
| +27% | +$899K |
|
1991
Beazer Homes USA
BZH
$872M
| $4M | ﹤0.01% |
283,400
+117,200
| +71% | +$1.78M |
|
|
CWBC
1992
Community West Bancshares
CWBC
$708M
| $4M | ﹤0.01% |
184,581
+26,100
| +16% | +$545K |
|
|
QTS
1993
DELISTED
QTS REALTY TRUST, INC.
QTS
| $4M | ﹤0.01% |
73,700
+66,900
| +984% | +$3.51M |
|
1994
Greif Class B
GEF.B
$4.2B
| $3.99M | ﹤0.01% |
77,110
+19,600
| +34% | +$973K |
|
1995
Global Ship Lease
GSL
$1.52B
| $3.99M | ﹤0.01% |
451,701
+148,826
| +49% | +$1.19M |
|
|
GTS
1996
DELISTED
Triple-S Management Corporation
GTS
| $3.98M | ﹤0.01% |
215,515
-249,451
| -54% | -$4.25M |
|
1997
Olin
OLN
$2.18B
| $3.98M | ﹤0.01% |
230,700
-81,100
| -26% | -$1.45M |
|
1998
AMES National
ATLO
$280M
| $3.96M | ﹤0.01% |
141,200
+12,200
| +9% | +$339K |
|
|
STEL
1999
DELISTED
Stellar Bancorp
STEL
| $3.96M | ﹤0.01% |
127,300
+79,000
| +164% | +$2.32M |
|
2000
Cummins
CMI
$86.9B
| $3.96M | ﹤0.01% |
+22,100
| New | +$3.89M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.